<DOC>
	<DOCNO>NCT02697591</DOCNO>
	<brief_summary>This open-label , non-randomized Phase 1/2 safety study INCAGN01876 subject advance metastatic solid tumor conduct 2 part . Part 1 determine pharmacologically active dose and/or maximum tolerate dose INCAGN01876 . Part 2 evaluate recommend dose determine Part 1 subject select tumor type .</brief_summary>
	<brief_title>An Open-Label , Dose-Escalation , Safety Study INCAGN01876 Subjects With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Locally advanced metastatic disease ; locally advanced disease must amenable resection curative intent Part 1 : Subjects advance metastatic solid tumor Part 2 : Subjects advance metastatic adenocarcinoma endometrium , melanoma , nonsmall cell lung cancer , renal cell carcinoma Subjects disease progression treatment available therapy know confer clinical benefit , intolerant treatment , subject refuse standard treatment Presence measureable disease base RECIST v1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Laboratory medical history parameter within protocoldefined range Receipt anticancer medication investigational drug within protocoldefined interval first administration study drug Has recover â‰¤ Grade 1 toxic effect prior therapy and/or complication prior surgical intervention start therapy Receipt live vaccine within 30 day plan start study therapy Active autoimmune disease require systemic treatment past 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>adenocarcinoma endometrium</keyword>
	<keyword>melanoma , non-small cell lung cancer ( NSCLC )</keyword>
	<keyword>renal cell carcinoma ( RCC )</keyword>
	<keyword>glucocorticoid-induced tumor necrosis factor receptor ( GITR )</keyword>
</DOC>